文献速递儿童呼吸儿童感染

美泊利单抗治疗城市儿童残余哮喘急性发作的炎症通路:随机临床试验二次分析

Inflammatory Pathways in Residual Asthma Exacerbations Among Mepolizumab-Treated Urban Children: A Secondary Analysis of a Randomized Clinical Trial.
PubMed 文献 · JAMA Pediatr · 2025-01-01

该研究为MUPPITS-2随机对照试验的二次分析,纳入290名易发作哮喘的城市儿童,其中108名在176次急性呼吸道疾病事件中采集鼻样本进行RNA测序模块分析。结果显示,美泊利单抗组在导致哮喘急性发作的疾病事件中,嗜酸性粒细胞相关T2炎症模块表达降低,但上皮和巨噬细胞炎症通路基因模块表达升高,且存在三种半正交炎症轴。

要点

  • 美泊利单抗组急性发作时嗜酸性粒细胞T2炎症模块表达降低(log2 FC -0.60)。
  • 美泊利单抗组急性发作时上皮和巨噬细胞炎症通路模块表达升高(log2 FC 0.22-0.85)。
  • 两组急性发作时黏液分泌和细胞应激反应通路表达均高于非急性发作疾病。

核心结论

  • 美泊利单抗治疗儿童残余急性发作与上皮和巨噬细胞炎症通路及黏液高分泌相关。
  • 多种不同炎症轴可独立促成哮喘急性发作。

研究设计与样本

  • MUPPITS-2随机双盲安慰剂对照平行组临床试验的二次分析。
  • 纳入美国9个低收入城市中心易发作哮喘儿童,美泊利单抗组6-11岁40mg、12-17岁100mg,每4周皮下注射一次,共52周。
  • 对176次急性呼吸道疾病事件的鼻样本进行RNA测序转录组模块分析,共108名参与者(中位年龄10.0岁,44%女性)。

主要发现

  • 两组在急性发作期间黏液分泌和细胞应激反应通路表达均高于非急性发作疾病。
  • 美泊利单抗组急性发作时上皮炎症通路上调不依赖呼吸道病毒,而巨噬细胞通路特异贡献于病毒性急性发作。
  • 三种不同的半正交炎症轴解释了两组急性发作的大部分异质性。

临床怎么用

  • 美泊利单抗治疗下仍需关注上皮和巨噬细胞炎症通路及黏液高分泌导致的残余急性发作。
  • 临床可考虑针对多种独立炎症轴的联合评估与干预策略。

局限性

  • 本研究为二次分析,样本量有限(108名参与者,176次事件)。
  • 原文未报告其他局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: While biologic therapies targeting type 2 (T2) inflammation reduce acute exacerbation rates in children with asthma and T2 inflammation, exacerbations still occur, and the underlying molecular mechanisms are poorly defined. OBJECTIVE: To identify multiple distinct molecular mechanisms implicated in asthma exacerbations by characterizing respiratory illnesses among urban children with eosinophilic asthma enrolled in a clinical trial comparing treatment with mepolizumab vs placebo. DESIGN, SETTING, AND PARTICIPANTS: This is a secondary analysis of the Mechanisms Underlying Asthma Exacerbations Prevented and Persistent With Immune-Based Therapy: A Systems Approach Phase 2 (MUPPITS-2) double-blind, placebo-controlled, parallel-group, randomized clinical trial comparing treatment with mepolizumab vs placebo among children with exacerbation-prone asthma in low-income urban centers in 9 US cities. Data analysis was performed from September 2022 to April 2025. INTERVENTION: Participants were randomized to receive either mepolizumab (aged 6-11 years: 40 mg; aged 12-17 years: 100 mg) or matching placebo by subcutaneous injection once every 4 weeks for 52 weeks. MAIN OUTCOMES AND MEASURES: The primary measurement was a transcriptomic modular analysis by RNA sequencing of nasal samples obtained during acute respiratory illnesses. Associations among upper airway transcriptional signatures, the clinical outcome of respiratory illnesses, and pulmonary functions were investigated. RESULTS: Of the 290 participants enrolled in the MUPPITS-2 trial, 108 participants (median [IQR] age, 10.0 [9.0-13.0] years; 48 [44%] female) were sampled during 176 acute respiratory illness events. During illness events resulting in asthma exacerbations, children receiving mepolizumab demonstrated decreased expression of an eosinophil-associated module associated with T2 inflammation (log2 fold change [FC] estimate, -0.60; false discovery rate [FDR] < .05) but increased expression of gene modules associated with epithelial and macrophage inflammatory pathways relative to children receiving placebo (log2 FC estimates, 0.22-0.85; FDR < .05). Both groups showed higher expression of mucus secretion and cellular stress response pathways during exacerbations relative to nonexacerbation illnesses. The mepolizumab group demonstrated upregulation of epithelial inflammatory pathways in exacerbations irrespective of a respiratory virus, while macrophage pathways contributed specifically to viral exacerbations. Three distinct, semiorthogonal inflammatory axes were shown to underlie the majority of the heterogeneity among exacerbations in the 2 groups. CONCLUSIONS AND RELEVANCE: The study's findings implicate multiple alternative inflammatory pathways associated with the epithelium and macrophages, as well as mucus hypersecretion, as mechanisms of residual acute exacerbations in children receiving mepolizumab. Further, they indicate that multiple distinct inflammatory axes can independently contribute to asthma exacerbations. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03292588.

来源:JAMA Pediatr,查看原文。版权归原作者所有。

引用

  1. Altman MC, Janczyk T, Murphy RC, et al. Inflammatory Pathways in Residual Asthma Exacerbations Among Mepolizumab-Treated Urban Children: A Secondary Analysis of a Randomized Clinical Trial. JAMA Pediatr. 2025. PMID: 40658400. doi:10.1001/jamapediatrics.2025.2044

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。